Purpose Pseudomonas aeruginosa bacteraemia is associated with high mortality, and most monotherapies are beta-lactam- based. We aimed to investigate clinical outcomes of den fi itive u fl oroquinolone monotherapy versus beta-lactam monotherapy for P. aeruginosa bacteraemia. Methods This retrospective study enrolled adult patients receiving definitive monotherapy with beta-lactam or fluoroqui - nolone between November 2013 and November 2014 at Taipei Veterans General Hospital. The independent risk factors for 28-day mortality were analyzed by logistic regression and propensity score-adjusted analysis. Results Among the 105 patients enrolled, 78 patients received beta-lactams and 27 received fluoroquinolones (20 with ciprofloxacin and 7 with levofloxacin). Primary bacteraemia (39.0%) and urinary tract infections (37.1%) were the most common sources of bacteraemia. The 28-day mortality rate was 11.1% for those receiving fluoroquinolones and 32.1% for those receiving beta-lactams (P = 0.062). The 28-day mortality rate between the two groups stratified by APACHE II and Pitt bacteraemia scores showed no significant differences in each category. Propensity score-adjusted multivariate analysis revealed that definitive therapy with a fluoroquinolone was not associated with 28-day mortality (OR 0.42; 95% CI 0.08–2.23; P = 0.305). Conclusions Fluoroquinolone might be an alternative to beta-lactam as a definitive monotherapy for P. aeruginosa bac- teraemia
Infection – Springer Journals
Published: Mar 20, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud